Ventipulmin Solution for Injection 30 micrograms/ml

Nchi: Ayalandi

Lugha: Kiingereza

Chanzo: HPRA (Health Products Regulatory Authority)

Viambatanisho vya kazi:

Clenbuterol hydrochloride

Inapatikana kutoka:

Boehringer Ingelheim Ltd

ATC kanuni:

QR03CC13

INN (Jina la Kimataifa):

Clenbuterol hydrochloride

Kipimo:

30 microgram(s)/millilitre

Dawa fomu:

Solution for injection

Dawa ya aina:

POM: Prescription Only Medicine as defined in relevant national legislation

Kundi la matibabu:

Horses

Eneo la matibabu:

clenbuterol

Matibabu dalili:

Respiratory Tract preparations

Idhini hali ya:

Authorised

Idhini ya tarehe:

1988-10-01

Tabia za bidhaa

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Ventipulmin Solution for Injection 30 micrograms/ml
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
Active substance:
Clenbuterol hydrochloride 30 micrograms
Preservative:
Benzyl alcohol (E1519) 10 mg
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
Clear colourless solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Horses.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of respiratory disease in horses where it is considered that
airway obstruction due to bronchospasm and/or
accumulation of mucus is a contributing factor, and improved
muco-ciliary clearance is desirable.
To be used alone or as
adjuvant therapy.
In particular:
i)
Acute, sub-acute and chronic respiratory allergies.
ii)
Acute, sub-acute and chronic infections where the presence of mucus
and/or micro-organisms may stimulate
bronchospasm or cause airway obstruction and thus an increase in
airway resistance.
For example, bronchitis, bronchiolitis
and bronchopneumonia alone, or associated with equine influenza and
other viral diseases.
iii)
Chronic Obstructive Pulmonary Disease (COPD).
In cases accompanied by bacterial infection the administration of
antimicrobial agents is recommended.
4.3 CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to the active
ingredient.
Do not use in horses with known cardiac disease.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_